Background:

This petition's goal is to address a pressing issue affecting cancer patients and their families in Ontario. Our beloved mothers, sisters, daughters, and family members have been waging a fierce battle against HER2-positive breast cancer, and for many, hope lies in the promising breast cancer drug, Enhertu. We stand united to call upon the Ontario Ministry of Health – Cancer Care Ontario to take urgent action and approve Enhertu under the New Drug Funding Program.

The Urgent Need:

We’ve witnessed the tremendous suffering cancer imposes on our loved ones. Our journey has been both heart-wrenching and inspiring, watching our mothers, sisters, daughters, and family members exhibit immense strength and resilience throughout their arduous treatment regimens. Now, our brave loved ones' healthcare teams have recommended Enhertu as a potential lifeline, offering new hope in their fight against this relentless disease.

While Enhertu has been approved in several provinces across Canada and even received federal approval, its unavailability under the Cancer Care Ontario New Drug Funding Program creates a significant financial burden for countless families. The treatment plan for Enhertu is prohibitively expensive, making it nearly impossible for many cancer patients to access this life-saving medication. The cost barrier stands as a large obstacle, preventing patients from receiving the treatment they desperately need to combat HER2-positive breast cancer.

Call to action:

We believe that every Ontarian facing HER2-positive breast cancer should have equal and timely access to the best available treatments. The Ontario Ministry of Health must act promptly to include Enhertu in the New Drug Funding Program, ensuring that no patient is denied this critical medication due to financial constraints.

Demands:

1. We urge the Ontario Ministry of Health to prioritize the approval of Enhertu under the Ontario New Drug Funding Program, without delay. We request that the government takes into consideration the proven benefits and medical recommendations surrounding Enhertu's usage when making this important decision.

2. We call upon the government to empathize with the financial burden cancer patients and their families face and take immediate action to ease the out-of-pocket expense associated with accessing Enhertu.

Conclusion:

We are united as we advocate for the approval of Enhertu in the Ontario New Drug Funding Program for cancer patients, including our beloved mothers, sisters, daughters, and family members who deserve the best possible chance to fight this disease.

We implore the Ontario Ministry of Health to recognize the urgency of this matter and take the necessary steps to ensure Enhertu's swift approval, giving our patients in Ontario battling HER2-positive breast cancer, the hope and healing they so deserve.